November 18, 2016 - By Ellis Scott · 0 Comments
Aradigm Corp (NASDAQ:ARDM) institutional sentiment decreased to 0.8 in Q2 2016. Its down -0.45, from 1.25 in 2016Q1. The ratio has dropped, as 5 active investment managers started new and increased positions, while 4 sold and decreased holdings in Aradigm Corp. The active investment managers in our partner’s database now own: 5.45 million shares, down from 5.48 million shares in 2016Q1. Also, the number of active investment managers holding Aradigm Corp in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 1 Increased: 2 New Position: 3.
Aradigm Corporation is a pharmaceutical firm focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The company has a market cap of $76.70 million. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It currently has negative earnings. It offers AERx pulmonary drug delivery platform and other technologies.
Aradigm Corporation (NASDAQ:ARDM) has risen 14.19% since April 18, 2016 and is uptrending. It has outperformed by 9.76% the S&P500.
According to Zacks Investment Research, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.”
Great Point Partners Llc holds 1.26% of its portfolio in Aradigm Corporation for 1.00 million shares. First Eagle Investment Management Llc owns 3.85 million shares or 0.04% of their US portfolio. Moreover, Point72 Asset Management L.P. has 0.01% invested in the company for 320,585 shares. The Massachusetts-based Acadian Asset Management Llc has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 28 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 1 insider sale for $2,859 net activity.
Aradigm Corporation, incorporated on January 30, 1991, is a specialty pharmaceutical firm focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. It is focused on commercializing its products in the United States, European Union (EU), Japan and China. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. The Firm offers AERx pulmonary drug delivery platform and other technologies. The Company’s partnered programs under development include Inhaled Ciprofloxacin. The Firm is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). The Firm is focused on inhaled nicotine product utilizing its AERx delivery system that is focused on addressing the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, could wean-off patients from cigarette smoking and from the nicotine addiction.
More important recent Aradigm Corporation (NASDAQ:ARDM) news were published by: Businesswire.com which released: “Aradigm Announces Third Quarter 2016 Financial Results” on November 09, 2016, also Businesswire.com published article titled: “Aradigm Corporation Announces First Closing of Private Placement Offering of …”, Businesswire.com published: “Aradigm Corporation Completes Enrollment in the Second Phase III Study of …” on October 13, 2015. More interesting news about Aradigm Corporation (NASDAQ:ARDM) was released by: Seekingalpha.com and their article: “6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity” with publication date: August 08, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott